Ivo Leuschner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ivo Leuschner has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Klingebiel
Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
5 shared publications - Dieter Harms
Institut für Pathologie, Universität Kiel, Arnold-Heller-Str. 3, Haus 14, 24105, Kiel, Deutschland,
3 shared publications - Ewa Koscielniak
Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany
3 shared publications Adrian Mattke
Department of Oncology/Haematology, Olga Hospital, Stuttgart, Germany
2 shared publications- Bernarda Kazanowska
Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland
2 shared publications - Christian Vokuhl
Department of Pathology, Division of Paidopathology, University Hospital Bonn University of Bonn Bonn Germany
2 shared publications
Latest Publications
- Open Access
- 14 October 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-8
Treatment and outcome of the patients with rhabdomyosarcoma of the biliary tree: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Biliary rhabdomyosarcoma (RMS) is the most common biliary tumor in children. The management of affected patients contains unique challenges because of the rarity of this tumor entity and its critical location at the porta hepatis, which can make achievement of a radical resection very difficult. In a retrospective chart analysis we analysed children suffering from biliary RMS who were registered in three different CWS trials (CWS-96, CWS-2002P, and SoTiSaR registry). Seventeen patients (12 female, 5 male) with a median age of 4.3 years were assessed. The median follow-up was 42.2 months (10.7–202.5). The 5-year overall (OS) and event free survival (EFS) rates were 58% (45–71) and 47% (34–50), respectively. Patients > 10 years of age and those with alveolar histology had the worst prognosis (OS 0%). Patients with botryoid histology had an excellent survival (OS 100%) compared to those with non-botryoid histology (OS 38%, 22–54, p = 0.047). Microscopic complete tumor resection was achieved in almost all patients who received initial tumor biopsy followed by chemotherapy and delayed surgery. Positive predictive factors for survival of children with biliary RMS are age ≤ 10 years and botryoid tumor histology. Primary surgery with intention of tumor resection should be avoided.
- 14 October 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-8
Open AccessTreatment and outcome of the patients with rhabdomyosarcoma of the biliary tree: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Biliary rhabdomyosarcoma (RMS) is the most common biliary tumor in children. The management of affected patients contains unique challenges because of the rarity of this tumor entity and its critical location at the porta hepatis, which can make achievement of a radical resection very difficult. In a retrospective chart analysis we analysed children suffering from biliary RMS who were registered in three different CWS trials (CWS-96, CWS-2002P, and SoTiSaR registry). Seventeen patients (12 female, 5 male) with a median age of 4.3 years were assessed. The median follow-up was 42.2 months (10.7–202.5). The 5-year overall (OS) and event free survival (EFS) rates were 58% (45–71) and 47% (34–50), respectively. Patients > 10 years of age and those with alveolar histology had the worst prognosis (OS 0%). Patients with botryoid histology had an excellent survival (OS 100%) compared to those with non-botryoid histology (OS 38%, 22–54, p = 0.047). Microscopic complete tumor resection was achieved in almost all patients who received initial tumor biopsy followed by chemotherapy and delayed surgery. Positive predictive factors for survival of children with biliary RMS are age ≤ 10 years and botryoid tumor histology. Primary surgery with intention of tumor resection should be avoided.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10527
Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS).
10527 Background: The optimal type and intensity of CHT in the treatment of STET is still a matter of debate. The CWS group has treated STET similar to rhabdomyosarcoma. We have analyzed the prognosis of STET in relation to the CHT regimens used in three consecutive CWS studies CWS-91, -96 and CWS- 2002P. Methods: 243 pts with localized STET were included. Their median age was 12 (range 0.1-29) yrs. In the CWS-91 pts with primary tumor resection (IRSG I and II) were treated with VACA (vincristine (VCR), actinomycin D (Act D), cyclophosphamide (CYC), doxorubicin (DOX), for 10 or 20 weeks. All other CWS-91 pts (high risk group, HRG) received EVAIA (ifosfamide (IFO) instead of CYC plus VP16) for 37 weeks. In the CWS-96 and CWS-2002P all STET pts were allocated to the HRG. In CWS-96 therapy was randomized: VAIA (IFO, DOX, Act D, VCR) vs. CEVAIE (Epi-DOX instead of DOX, plus carboplatin and VP16), for 25 weeks. In CWS-2002P VAIA (25 weeks) plus maintenance CHT with CYC and vinblastine (VBL) for 26 weeks were used. The cumulative doses varied: IFO 24-72 g/m², CYC 4.8-7.35 g/m², DOX 120-360 mg/m², Act D 3-9 mg/m², VP16 1.8-5.4 g/m². Irradiation was stratified depending on results of the primary or secondary resection and response. Results: 5 yr event free (EFS) and overall survival (OS) were 64% and 73%. The median observation time of survivors was 9 yrs. 5yr EFS and OS by study were: CWS-91 64 % and 72 %, CWS-96 57% and 70 %, CWS-2002P 78 % and 86 % respectively (n.s.). 5 yr EFS and OS for VACA arm were 79% and 90%. 5 yr EFS and OS by CHT for HRG were: EVAIA 57% and 65%, VAIA 64% and 80%, CEVAIE 45% and 54%, VAIA with CYC/VBL 84% and 87%, respectively (p = 0 .003). 5yr EFS and OS for irradiated (n = 181) vs. not irradiated (n = 48) patients were 63 % and 72% vs. 63% and 79%, respectively. Conclusions: The outcomes between CHT arms differed significantly: CEVAIA correlated with the worst outcome while VAIA with CYC/VBL showed the best results. A small group of low risk patients have an excellent prognosis with substantially reduced CHT. Ewing tumors are biologically heterogeneous and more diversification in therapy stratification is warranted to avoid overtreatment.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10527
Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS).
10527 Background: The optimal type and intensity of CHT in the treatment of STET is still a matter of debate. The CWS group has treated STET similar to rhabdomyosarcoma. We have analyzed the prognosis of STET in relation to the CHT regimens used in three consecutive CWS studies CWS-91, -96 and CWS- 2002P. Methods: 243 pts with localized STET were included. Their median age was 12 (range 0.1-29) yrs. In the CWS-91 pts with primary tumor resection (IRSG I and II) were treated with VACA (vincristine (VCR), actinomycin D (Act D), cyclophosphamide (CYC), doxorubicin (DOX), for 10 or 20 weeks. All other CWS-91 pts (high risk group, HRG) received EVAIA (ifosfamide (IFO) instead of CYC plus VP16) for 37 weeks. In the CWS-96 and CWS-2002P all STET pts were allocated to the HRG. In CWS-96 therapy was randomized: VAIA (IFO, DOX, Act D, VCR) vs. CEVAIE (Epi-DOX instead of DOX, plus carboplatin and VP16), for 25 weeks. In CWS-2002P VAIA (25 weeks) plus maintenance CHT with CYC and vinblastine (VBL) for 26 weeks were used. The cumulative doses varied: IFO 24-72 g/m², CYC 4.8-7.35 g/m², DOX 120-360 mg/m², Act D 3-9 mg/m², VP16 1.8-5.4 g/m². Irradiation was stratified depending on results of the primary or secondary resection and response. Results: 5 yr event free (EFS) and overall survival (OS) were 64% and 73%. The median observation time of survivors was 9 yrs. 5yr EFS and OS by study were: CWS-91 64 % and 72 %, CWS-96 57% and 70 %, CWS-2002P 78 % and 86 % respectively (n.s.). 5 yr EFS and OS for VACA arm were 79% and 90%. 5 yr EFS and OS by CHT for HRG were: EVAIA 57% and 65%, VAIA 64% and 80%, CEVAIE 45% and 54%, VAIA with CYC/VBL 84% and 87%, respectively (p = 0 .003). 5yr EFS and OS for irradiated (n = 181) vs. not irradiated (n = 48) patients were 63 % and 72% vs. 63% and 79%, respectively. Conclusions: The outcomes between CHT arms differed significantly: CEVAIA correlated with the worst outcome while VAIA with CYC/VBL showed the best results. A small group of low risk patients have an excellent prognosis with substantially reduced CHT. Ewing tumors are biologically heterogeneous and more diversification in therapy stratification is warranted to avoid overtreatment.
- Open Access
- 27 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-11
Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006)
- 27 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-11
Open AccessTreatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006)
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10529
Prognosis of patients with parameningeal rhabdomyosarcoma (PM-RMS): The long term results of five consecutive CWS studies 1981-2009.
10529 Background: PM sites (nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space) are considered as unfavorable factor in RMS. Due to their proximity to skull base they have high risk of meningeal impingement, including cranial nerve palsy (CNP), cranial base bony erosion (CBBE) and intracranial extension (ICE). Our goal was to compare treatment strategies and outcome of patients with localized PM RMS enrolled on five consecutive CWS studies -81 -86, -91, -96 and -2002P. Methods: A total of 404 patients were included. All patients received intensive chemotherapy (3 to 6 drugs: alkylating agents - cyclophosphamide or ifosfamide, actinomycin D, doxorubicin, vincristine, carboplatin and etoposide. Radiotherapy was indicated for all patients except for children < 1 year of age. Irradiation (RT) dose was stratified depending on meningeal involvement, response, histological subtype and age and varied between the studies (32 - 54,4 Gy). Accelarated hyperfractionation was recommended since CWS-86. Proton radiation was recommended if available. Results: The majority of tumors were classified into IRS Group III (95%) and had embryonal type (78%). 85% achieved complete remission, 22 % relapsed, 15% local. The 5yrs event free survival (EFS) and overall survival (OS) was 61% and 65%. 5yrs EFS by study was CWS-81: 42%, CWS-86: 63%, CWS-91: 63%, CWS-96: 62%, CWS 2002P: 66%. Patients with ICE had worst outcome but no difference was seen depending on CNP and CBBE. 92% of patients were irradiated. The median time from initiation of chemotherapy to RT was 14 weeks (range 2-30). 5yrs EFS depending on RT start ( < 10 weeks, > 10 < 20 weeks, > 20 < 30 weeks) did not differ (65%, 67%, 68%). Three patients groups depending on their RT dose: 32-36 Gy, 44-49 Gy, 50-55 Gy showed similar outcome (5yrs EFS 70% vs.68% vs. 67% respectively). Only patients irradiated with > 57 Gy or without RT had significantly worse outcome (5yrs EFS 30%). Conclusions: The outcome has improved between CWS-81 and CWS-86 only. No benefit of very early ( < 10 weeks) or higher irradiation doses was seen.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10529
Prognosis of patients with parameningeal rhabdomyosarcoma (PM-RMS): The long term results of five consecutive CWS studies 1981-2009.
10529 Background: PM sites (nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space) are considered as unfavorable factor in RMS. Due to their proximity to skull base they have high risk of meningeal impingement, including cranial nerve palsy (CNP), cranial base bony erosion (CBBE) and intracranial extension (ICE). Our goal was to compare treatment strategies and outcome of patients with localized PM RMS enrolled on five consecutive CWS studies -81 -86, -91, -96 and -2002P. Methods: A total of 404 patients were included. All patients received intensive chemotherapy (3 to 6 drugs: alkylating agents - cyclophosphamide or ifosfamide, actinomycin D, doxorubicin, vincristine, carboplatin and etoposide. Radiotherapy was indicated for all patients except for children < 1 year of age. Irradiation (RT) dose was stratified depending on meningeal involvement, response, histological subtype and age and varied between the studies (32 - 54,4 Gy). Accelarated hyperfractionation was recommended since CWS-86. Proton radiation was recommended if available. Results: The majority of tumors were classified into IRS Group III (95%) and had embryonal type (78%). 85% achieved complete remission, 22 % relapsed, 15% local. The 5yrs event free survival (EFS) and overall survival (OS) was 61% and 65%. 5yrs EFS by study was CWS-81: 42%, CWS-86: 63%, CWS-91: 63%, CWS-96: 62%, CWS 2002P: 66%. Patients with ICE had worst outcome but no difference was seen depending on CNP and CBBE. 92% of patients were irradiated. The median time from initiation of chemotherapy to RT was 14 weeks (range 2-30). 5yrs EFS depending on RT start ( < 10 weeks, > 10 < 20 weeks, > 20 < 30 weeks) did not differ (65%, 67%, 68%). Three patients groups depending on their RT dose: 32-36 Gy, 44-49 Gy, 50-55 Gy showed similar outcome (5yrs EFS 70% vs.68% vs. 67% respectively). Only patients irradiated with > 57 Gy or without RT had significantly worse outcome (5yrs EFS 30%). Conclusions: The outcome has improved between CWS-81 and CWS-86 only. No benefit of very early ( < 10 weeks) or higher irradiation doses was seen.
- 21 August 2015
- Published by Springer Nature in Der Pathologe
- Vol. 36 (5) , 443-450
Histiozytäre Erkrankung des Kindes- und Jugendalters
Histiocytic diseases are generally rare with a variable clinical course and variable morphology which often have a peak frequency of occurrence in childhood and adolescence. Histiocytoses are subdivided into Langerhans cell histiocytosis and the so-called non-Langerhans cell histiocytosis, such as juvenile xanthogranuloma, Erdheim-Chester disease and Rosai-Dorfman disease. The most common forms of histiocytosis in childhood are Langerhans cell histiocytosis and juvenile xanthogranuloma. In contrast, forms of histiocytosis which occur more frequently in adulthood, such as Erdheim-Chester disease and Rosai-Dorfman disease are rare in childhood. Some forms of histiocytosis harbor BRAFv600E mutations. In Langerhans cell histiocytosis they have been found in 50-55 % of the cases examined and in Erdheim-Chester disease in up to 100 % of cases. In the remaining forms of histiocytosis (especially juvenile xanthogranuloma and Rosai-Dorfman disease) BRAF mutations could not be detected. A prognostic relevance could not be shown so far; however, in individual cases a mutation analysis of BRAF could provide help in the differential diagnostic considerations or the option of a therapy approach with BRAF inhibitors.
- 21 August 2015
- Published by Springer Nature in Der Pathologe
- Vol. 36 (5) , 443-450
Histiozytäre Erkrankung des Kindes- und Jugendalters
Histiocytic diseases are generally rare with a variable clinical course and variable morphology which often have a peak frequency of occurrence in childhood and adolescence. Histiocytoses are subdivided into Langerhans cell histiocytosis and the so-called non-Langerhans cell histiocytosis, such as juvenile xanthogranuloma, Erdheim-Chester disease and Rosai-Dorfman disease. The most common forms of histiocytosis in childhood are Langerhans cell histiocytosis and juvenile xanthogranuloma. In contrast, forms of histiocytosis which occur more frequently in adulthood, such as Erdheim-Chester disease and Rosai-Dorfman disease are rare in childhood. Some forms of histiocytosis harbor BRAFv600E mutations. In Langerhans cell histiocytosis they have been found in 50-55 % of the cases examined and in Erdheim-Chester disease in up to 100 % of cases. In the remaining forms of histiocytosis (especially juvenile xanthogranuloma and Rosai-Dorfman disease) BRAF mutations could not be detected. A prognostic relevance could not be shown so far; however, in individual cases a mutation analysis of BRAF could provide help in the differential diagnostic considerations or the option of a therapy approach with BRAF inhibitors.
- 18 July 2014
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 53 (11) , 960-962
1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial
- 18 July 2014
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 53 (11) , 960-962
1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial
- 3 November 2012
- Published by Springer Nature
- p. 727-802
Pathologie der Kindertumoren
- 28 August 2010
- Published by Springer Nature in Der Pathologe
- Vol. 31 (S2) , 314-315
Bericht über die Arbeitsgemeinschaft Paidopathologie
- 28 August 2010
- Published by Springer Nature in Der Pathologe
- Vol. 31 (S2) , 314-315
Bericht über die Arbeitsgemeinschaft Paidopathologie
- 16 January 2010
- Published by Springer Nature in Der Pathologe
- Vol. 31 (2) , 150-152
Lipofibromatose bei einem 6-jährigen Mädchen
Lipofibromatosis is a typical soft tissue lesion of childhood which is most likely underdiagnosed. The case of a 6-year-old girl with a palmar tumor is presented. The lesion showed a typical fascicular growth patter into the fatty tissue. Differential diagnosis includes fibrous hamartoma of infancy. Lipofibromatosis is a benign disease but recurrences are not unusual.
- 16 January 2010
- Published by Springer Nature in Der Pathologe
- Vol. 31 (2) , 150-152
Lipofibromatose bei einem 6-jährigen Mädchen
Lipofibromatosis is a typical soft tissue lesion of childhood which is most likely underdiagnosed. The case of a 6-year-old girl with a palmar tumor is presented. The lesion showed a typical fascicular growth patter into the fatty tissue. Differential diagnosis includes fibrous hamartoma of infancy. Lipofibromatosis is a benign disease but recurrences are not unusual.